Hosted on MSN4h
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
Medpage Today on MSN21h
Which High-Risk Patients Should Get the RSV Vaccine?The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
TipRanks on MSN10h
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...
GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback